Brokerages expect GALAPAGOS NV/S (NASDAQ:GLPG) to report earnings per share (EPS) of ($0.65) for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for GALAPAGOS NV/S’s earnings. The lowest EPS estimate is ($1.22) and the highest is $0.40. GALAPAGOS NV/S reported earnings of ($0.85) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 23.5%. The firm is expected to announce its next earnings results on Tuesday, October 23rd.

On average, analysts expect that GALAPAGOS NV/S will report full year earnings of ($3.12) per share for the current financial year, with EPS estimates ranging from ($3.94) to ($1.87). For the next fiscal year, analysts forecast that the firm will report earnings of ($3.84) per share, with EPS estimates ranging from ($4.64) to ($2.96). Zacks’ earnings per share calculations are an average based on a survey of analysts that follow GALAPAGOS NV/S.

GALAPAGOS NV/S (NASDAQ:GLPG) last announced its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.41. The firm had revenue of $59.27 million for the quarter, compared to analyst estimates of $50.58 million. GALAPAGOS NV/S had a negative net margin of 70.80% and a negative return on equity of 13.26%.

A number of brokerages have recently weighed in on GLPG. Royal Bank of Canada cut their target price on shares of GALAPAGOS NV/S to $94.00 and set a “sector perform” rating on the stock in a research note on Friday, June 29th. Zacks Investment Research lowered shares of GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. Morgan Stanley lifted their target price on shares of GALAPAGOS NV/S from $126.00 to $127.00 and gave the company an “overweight” rating in a research note on Monday, August 6th. BidaskClub lowered shares of GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research note on Thursday, June 14th. Finally, Goldman Sachs Group reissued a “neutral” rating on shares of GALAPAGOS NV/S in a research note on Friday, August 17th. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $113.71.

A number of large investors have recently bought and sold shares of GLPG. Victory Capital Management Inc. boosted its stake in GALAPAGOS NV/S by 11.3% during the first quarter. Victory Capital Management Inc. now owns 20,356 shares of the biotechnology company’s stock worth $2,031,000 after acquiring an additional 2,060 shares in the last quarter. Aperio Group LLC boosted its stake in GALAPAGOS NV/S by 22.3% during the first quarter. Aperio Group LLC now owns 9,300 shares of the biotechnology company’s stock worth $928,000 after acquiring an additional 1,697 shares in the last quarter. Employees Retirement System of Texas boosted its stake in GALAPAGOS NV/S by 3.7% during the first quarter. Employees Retirement System of Texas now owns 56,000 shares of the biotechnology company’s stock worth $5,587,000 after acquiring an additional 2,000 shares in the last quarter. Landscape Capital Management L.L.C. boosted its stake in GALAPAGOS NV/S by 235.5% during the first quarter. Landscape Capital Management L.L.C. now owns 13,895 shares of the biotechnology company’s stock worth $1,386,000 after acquiring an additional 9,754 shares in the last quarter. Finally, Citadel Advisors LLC boosted its stake in GALAPAGOS NV/S by 24.3% during the first quarter. Citadel Advisors LLC now owns 3,566 shares of the biotechnology company’s stock worth $356,000 after acquiring an additional 696 shares in the last quarter. 14.64% of the stock is currently owned by institutional investors and hedge funds.

Shares of GLPG opened at $112.00 on Wednesday. The stock has a market cap of $5.81 billion, a PE ratio of -42.42 and a beta of 2.03. GALAPAGOS NV/S has a 1-year low of $84.13 and a 1-year high of $122.28.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

See Also: Exchange-Traded Funds (ETFs)

Get a free copy of the Zacks research report on GALAPAGOS NV/S (GLPG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.